HC Wainwright Expects Stronger Earnings for Compass Pathways

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Compass Pathways in a report released on Monday, November 9th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($1.40) per share for the year, up from their prior estimate of ($1.58). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.38) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.17) EPS.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “sell” rating in a report on Sunday. Oppenheimer reiterated an “outperform” rating and set a $20.00 target price on shares of Compass Pathways in a report on Tuesday, November 3rd. B. Riley Financial lifted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Thursday, October 15th. Finally, Wells Fargo & Company cut their price target on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average price target of $23.14.

Compass Pathways Trading Up 0.8%

Shares of NASDAQ CMPS opened at $9.25 on Wednesday. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The stock has a market cap of $1.31 billion, a P/E ratio of -2.65 and a beta of 2.43. The firm has a 50-day moving average of $12.14 and a 200 day moving average of $10.43. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50.

Hedge Funds Weigh In On Compass Pathways

Several large investors have recently modified their holdings of CMPS. Orbimed Advisors LLC bought a new position in Compass Pathways in the 1st quarter worth about $6,363,000. Affinity Asset Advisors LLC grew its position in Compass Pathways by 454.2% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock valued at $6,130,000 after purchasing an additional 908,483 shares during the last quarter. Eversept Partners LP bought a new stake in Compass Pathways during the 1st quarter valued at about $3,749,000. Creek Drive Management Group LLC increased its stake in Compass Pathways by 91.9% during the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock valued at $16,520,000 after purchasing an additional 636,000 shares in the last quarter. Finally, CenterBook Partners LP increased its stake in Compass Pathways by 454.1% during the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after purchasing an additional 570,349 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.